Progress in Drug Research: Volume 55

· Progress in Drug Research Libro 55 · Birkhäuser
Ebook
336
pagine
Valutazioni e recensioni non sono verificate  Scopri di più

Informazioni su questo ebook

Hepatitis C virus (HCV) was first identified in 1989 as the etiologic agent of non-A, non-B hepatitis [1] and is currently recognized as the leading cause of chronic liver disease worldwide. In contrast to hepatitis B virus infection, in which only about 5% of adult infections become chronic, more than 80% of HCV-infected patients develop chronic hepatitis. Moreover, 20-50% of those persistently infected with HCV will develop liver cirrhosis and hepatocellu lar carcinoma (HCC) [2]. It is estimated that there are 10,000 deaths in the USA per year due to chronic liver failure or HCC [3]. In addition, HCV dis 25-50% of all liver transplants in US centers, and the ease is responsible for recurrence of HCV infection following liver transplantation is universal [4]. Typically, HCV disease emerges after a 10-20 year period during which symp toms, if they exist at all, are mild and non-specific. Although the prevalence varies greatly among different countries, it has been estimated that up to 170 million people (3% of the world's population), are infected with HCV [5]. A recent study in the USA found that 65% of all HCV-infected persons are 30 to 49 years old [6].

Valuta questo ebook

Dicci cosa ne pensi.

Informazioni sulla lettura

Smartphone e tablet
Installa l'app Google Play Libri per Android e iPad/iPhone. L'app verrà sincronizzata automaticamente con il tuo account e potrai leggere libri online oppure offline ovunque tu sia.
Laptop e computer
Puoi ascoltare gli audiolibri acquistati su Google Play usando il browser web del tuo computer.
eReader e altri dispositivi
Per leggere su dispositivi e-ink come Kobo e eReader, dovrai scaricare un file e trasferirlo sul dispositivo. Segui le istruzioni dettagliate del Centro assistenza per trasferire i file sugli eReader supportati.